#FDA just approved Qalsody (tofersen) for #ALS with #SOD1 mutation (~2% of ALS cases), based on a ⬇️ of the #biomarker neurofilament (NFL) in the plasma.
🔹 ALS is a progressive neurodegenerative disorder, attacking nerve cells that control voluntary muscles (e.g., breathing)
🔹 Qalsody is given intrathecally (in the spine) with 3 initial doses at 14-day intervals and maintenance every 28 days
🔹 Most common side effects were pain, fatigue, joint pain, ⬆️ white blood cells in the CSF, and muscle pain

Cover feature in issue 42/2:

#Golgi #oxygen sensor controlling #intestinal ‘mucin #glycosylation
by Tal Ilani, Deborah Fass and colleagues with SciStories.com

And:
Gut colonization via #GTPase-less EF-G paralog
#Yeast cells in two minds about #cellcycle start
#MASTL/#PP2A module restraining #PI3K-Akt
Zinc-dependent structural transition in ALS-mutated #SOD1
https://www.embopress.org/toc/14602075/2023/42/2